USPTO Art Unit 1629 Prosecution Statistics

Art Unit Information

Art Unit: 1629
Group: 1620
Tech Center: 1600
Total Cases: 12,909
Last Active: February 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19050547TREATMENT FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION WITH GUANETHIDINE AND GUANADRELFebruary 2025June 2025Allow410NoNo
19039220METHODS OF TREATING ISCHEMIC STROKE AT RISK FOR CEREBRAL OR CEREBELLAR EDEMAJanuary 2025May 2025Allow310NoNo
19020628GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USEJanuary 2025June 2025Allow510YesNo
19018788COMPOUNDS AS GLP-1R AGONISTSJanuary 2025June 2025Allow510YesNo
19018805COMPOUNDS AS GLP-1R AGONISTSJanuary 2025June 2025Allow510YesNo
19018817COMPOUNDS AS GLP-1R AGONISTSJanuary 2025June 2025Allow510YesNo
19018754COMPOUNDS AS GLP-1R AGONISTSJanuary 2025May 2025Allow510YesNo
19018773COMPOUNDS AS GLP-1R AGONISTSJanuary 2025May 2025Allow510YesNo
18999662EPINEPHRINE COMPOSITIONS AND CONTAINERSDecember 2024May 2025Allow410NoNo
18990351METHODS OF IMPROVING RENAL FUNCTIONDecember 2024June 2025Allow610NoNo
18986934METHOD OF TREATING CANCER WITH A SELENIDEDecember 2024March 2025Allow310NoNo
18958449Compositions And Methods For The Treatment Of DepressionNovember 2024June 2025Allow710NoNo
18949105PARTICULATE COMPOSITIONNovember 2024January 2025Allow200YesNo
18945317GLABRIDIN COMPOSITION WITH HIGH SKIN PERMEABILITY, AND PREPARATION METHOD AND USE THEREOFNovember 2024February 2025Allow300YesNo
18943210NASAL COMPOSITIONS COMPRISING ALCAFTADINENovember 2024March 2025Allow400NoNo
18941137PHARMACEUTICAL COMPOSITIONS COMPRISING NILOTINIBNovember 2024June 2025Allow720YesNo
18938942Oral Testosterone TherapyNovember 2024January 2025Allow210NoNo
18937891TREATMENT OF PROSTATE CANCERNovember 2024May 2025Allow610NoNo
18913072METHODS OF TREATING MIGRAINEOctober 2024June 2025Allow811YesNo
18899500COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONSSeptember 2024December 2024Allow310NoNo
18895208METHOD OF TREATING CANCER IN A SUBJECTSeptember 2024November 2024Allow200NoNo
18892208KRAS MODULATORS AND USES THEREOFSeptember 2024March 2025Allow610YesNo
18818317STABLE PSILOCIN SALTS, ESTERS AND CONJUGATES AND USES THEREOFAugust 2024November 2024Allow210NoNo
18811682COMPOSITIONS AND METHODS FOR USING ENGINEERED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELLULAR PROCESSESAugust 2024March 2025Allow710NoNo
18811674COMPOSITIONS AND METHODS FOR USING ENGINEERED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELLULAR PROCESSESAugust 2024March 2025Allow610NoNo
18811171Compositions and Methods for Treating Hypertension by Modulating Endocrine ActivityAugust 2024November 2024Allow310NoNo
18838986BRIDGED RING COMPOUNDS AND THEIR THERAPEUTIC USE AS CNS AGENTSAugust 2024May 2025Allow900NoNo
18796081COMPOSITIONS AND METHODS FOR USING ENGINEERED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELLULAR PROCESSESAugust 2024January 2025Allow610NoNo
18778617AGENTS THAT TARGET TELOMERASE REVERSE TRANSCRIPTASE (TERT) FOR TREATING CANCER AND SENSITIZING CANCER CELLS TO GENOTOXIC THERAPYJuly 2024June 2025Allow1121YesNo
18775916CRYSTALLINE FORMS OF (S, E)-4-(DIMETHYLAMINO)-N-(3-(4-(2-HYDROXY-1-PHENYLETHYLAMINO)-6-PHENYLFURO[2,3-D]PYRIMIDIN-5-YL)PHENYL)BUT-2-ENAMIDE FREE BASEJuly 2024October 2024Abandon310NoNo
18771595METHODS OF TREATING FIBROTIC LIVER DISEASES OR CONDITIONS WITH INDEGLITAZARJuly 2024November 2024Allow400NoNo
18763671PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF A CANCERJuly 2024December 2024Allow510NoNo
18761559DEUTERATED ORGANIC COMPOUNDS AND USES THEREOFJuly 2024March 2025Allow810YesNo
18758242METHODS FOR TREATING HETEROTOPIC OSSIFICATIONJune 2024September 2024Allow300NoNo
18758904TREATMENT OF PROSTATE CANCERJune 2024August 2024Allow200NoNo
18758358GAMMA-HYDROXYBUTYRATE COMPOSITIONS HAVING IMPROVED PHARMACOKINETICS IN THE FED STATEJune 2024October 2024Allow410YesNo
18758344GAMMA-HYDROXYBUTYRATE COMPOSITIONS HAVING IMPROVED PHARMACOKINETICS IN THE FED STATEJune 2024October 2024Allow410YesNo
18755445METHODS OF TREATING FIBROSISJune 2024November 2024Allow510NoNo
18753759PARTICULATE COMPOSITIONJune 2024September 2024Allow300YesNo
18734541METHODS OF TREATING ISCHEMIC STROKE AT RISK FOR CEREBRAL OR CEREBELLAR EDEMAJune 2024January 2025Allow710YesNo
18734388METHODS OF TREATING ISCHEMIC STROKE AT RISK FOR CEREBRAL OR CEREBELLAR EDEMAJune 2024December 2024Allow611YesNo
18733183METHOD OF TREATING CANCER AND BONE CANCER PAINJune 2024June 2025Abandon1310NoNo
18674761PHARMACEUTICAL COMPOSITIONS COMPRISING A TOLFENAMIC ACIDMay 2024December 2024Allow710NoNo
18671935SULFONYLHYDRAZIDE DERIVATIVES AS ANTICANCER AGENTSMay 2024December 2024Allow701YesNo
18670277INJECTABLE BUPRENORPHINE FORMULATIONMay 2024April 2025Allow1110NoNo
18670637EFFECTIVE TREATMENT OF DEPRESSION IN PATIENTS HAVING IMPAIRED LEARNING AND/OR MEMORY OR CERTAIN EEG CHARACTERISTICS WITH A BENZYLPIPERAZINE-AMINOPYRIDINE AGENTMay 2024September 2024Allow410NoNo
18670041COMPOUNDED COMPOSITIONS AND METHODS FOR TREATING PAINMay 2024March 2025Allow1021NoNo
18670627EFFECTIVE TREATMENT OF DEPRESSION IN PATIENTS HAVING IMPAIRED LEARNING AND/OR MEMORY OR CERTAIN EEG CHARACTERISTICS WITH A BENZYLPIPERAZINE-AMINOPYRIDINE AGENTMay 2024September 2024Allow420YesNo
18660997AGENT FOR REDUCING VISCERAL FAT WEIGHTMay 2024June 2025Abandon1310NoNo
18708597MONTELUKAST BERBERINE QUATERNARY AMMONIUM SALT COMPOUND AND DOUBLE SALT COMPOSITION, AND SYNTHESIS METHOD THEREFOR AND USE THEREOFMay 2024September 2024Allow400NoNo
18659413PSYCHOACTIVE MEDICINES AND THEIR USE FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS AND DISORDERSMay 2024December 2024Allow711YesNo
18657665METHODS FOR MAKING AND USING ENDOXIFENMay 2024December 2024Allow700NoNo
18657123N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOFMay 2024February 2025Allow910YesNo
18655793HALOGENATED PSILOCYBIN DERIVATIVES AND METHODS OF USINGMay 2024August 2024Allow301YesNo
18654926Testosterone Dodecanoate Compositions and MethodsMay 2024February 2025Allow921NoNo
18653685New Centrally-Active Ghrelin Agonist and Medical Uses ThereofMay 2024May 2025Allow1220NoNo
18653318RESCUE TREATMENT OF POST OPERATIVE NAUSEA AND VOMITINGMay 2024February 2025Allow1010NoNo
18653610ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINSMay 2024November 2024Allow710NoNo
18653655ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINSMay 2024November 2024Allow710NoNo
18643034ESKETAMINE FOR THE TREATMENT OF DEPRESSIONApril 2024February 2025Abandon1010NoNo
18641597Oral Testosterone TherapyApril 2024July 2024Allow310NoNo
18637711METHODS FOR TREATING HETEROTOPIC OSSIFICATIONApril 2024June 2024Allow200NoNo
18633460COMPOUNDS AS MYT1 INHIBITORSApril 2024August 2024Allow410YesNo
18628353METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS)April 2024March 2025Abandon1110NoNo
18628366METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS)April 2024March 2025Abandon1210NoNo
18627708METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTIONApril 2024August 2024Allow510NoNo
18625188SESQUITERPENOID DERIVATIVE AND USE THEREOF IN PREPARING BROAD-SPECTRUM ANTIVIRAL DRUGApril 2024October 2024Allow710NoNo
18621682Isotopically Modified Composition and Therapeutic Uses ThereofMarch 2024April 2025Abandon1310NoNo
18622139Formulation of ResiniferatoxinMarch 2024May 2025Abandon1410NoNo
18621541METHOD OF INCREASING LIFESPAN IN MAMMALSMarch 2024October 2024Allow710NoNo
18621067METHODS OF TREATING ACUTE DEPRESSIONMarch 2024March 2025Allow1110NoNo
18620110INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOFMarch 2024August 2024Allow500NoNo
18620036INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOFMarch 2024June 2024Allow300NoNo
18616636LPXC INHIBITORS AND USES THEREOFMarch 2024October 2024Allow710NoNo
18615452Compositions and Methods for Treating Hypertension by Modulating Endocrine ActivityMarch 2024August 2024Allow511NoNo
18613270PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASEMarch 2024June 2024Allow300YesNo
18612156IRAK4 InhibitorsMarch 2024July 2024Allow400NoNo
18611026METHOD FOR PRODUCING 1,3-DIOLEIN FROM BIOMASSMarch 2024August 2024Allow500YesNo
18608735DOSAGE FORMS OF MIRDAMETINIBMarch 2024May 2024Allow200NoNo
18604836SYNTHETIC METHODS FOR PREPARATION OF 4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-N-[(1S)-2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)ETHYL]-5-METHYL-N-PROP-2-YNYL-1,3-THIAZOL-2-AMINEMarch 2024May 2024Allow200NoNo
18600974HETEROCYCLIC PDK1 INHIBITORS FOR USE TO TREAT CANCERMarch 2024June 2025Abandon1501NoNo
18601926METHODS OF USING DMTMarch 2024June 2025Allow1520YesNo
18596341COMPOSITIONS AND METHODS FOR TREATING POLYCYTHEMIAMarch 2024December 2024Abandon1010NoNo
18592795Compositions and Methods for Improving the Solubility of Erectile Dysfunction TherapeuticsMarch 2024July 2024Allow510NoNo
18584914ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINSFebruary 2024July 2024Allow510NoNo
18437920NON-VASOCONSTRICTING ENERGY-PROMOTING COMPOSITIONS CONTAINING KETONE BODIESFebruary 2024July 2024Allow610NoNo
18437724COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDILFebruary 2024November 2024Allow901YesNo
18437405Oral (17-�)-3-Oxoandrost-4-EN-17-YL Tridecanoate TherapyFebruary 2024July 2024Allow510NoNo
18437931EPINEPHRINE COMPOSITIONS AND CONTAINERSFebruary 2024April 2025Allow1420YesYes
184372295-(2,4,5-TRIS(4-CHLOROPHENYL)-1H-IMIDAZOL-1-YL)PENTANOIC ACID AS AN ANTIMICROBIAL COMPOUNDFebruary 2024May 2024Allow300NoNo
18434159SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) TARGETED THERAPEUTICS AND USES THEREOFFebruary 2024September 2024Allow720YesNo
18431262COMBINATION THERAPY FOR TREATING CANCERFebruary 2024May 2025Abandon1501NoNo
18430855OPHTHALMIC SOLUTION OF DIFLUPREDNATEFebruary 2024April 2025Allow1420YesNo
18428087REGULATION OF eIF4E ACTIVITY FOR MIGRAINE THERAPYJanuary 2024March 2025Allow1310NoNo
18428522FORMULATIONS OF AN AXL/MER INHIBITORJanuary 2024February 2025Allow1200NoNo
18428937Compositions And Methods For The Treatment Of DepressionJanuary 2024July 2024Allow520NoNo
18428542THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTIONJanuary 2024October 2024Allow821NoNo
18423029METHODS FOR TREATING CHOLESTASISJanuary 2024April 2025Allow1530NoNo
18422531COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONSJanuary 2024September 2024Allow820YesNo
18421934THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASESJanuary 2024December 2024Abandon1111NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1629.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
165
Examiner Affirmed
128
(77.6%)
Examiner Reversed
37
(22.4%)
Reversal Percentile
9.0%
Lower than average

What This Means

With a 22.4% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
1046
Allowed After Appeal Filing
185
(17.7%)
Not Allowed After Appeal Filing
861
(82.3%)
Filing Benefit Percentile
2.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 17.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1629 - Prosecution Statistics Summary

Executive Summary

Art Unit 1629 is part of Group 1620 in Technology Center 1600. This art unit has examined 12,909 patent applications in our dataset, with an overall allowance rate of 58.8%. Applications typically reach final disposition in approximately 27 months.

Comparative Analysis

Art Unit 1629's allowance rate of 58.8% places it in the 13% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1629 receive an average of 1.77 office actions before reaching final disposition (in the 45% percentile). The median prosecution time is 27 months (in the 59% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is shorter than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.